Circulating Dermatan Sulfate and Heparan Sulfate/Heparin Proteoglycans in Children Undergoing Liver Transplantation

Lesley Mitchell; Ricardo Superina; Michael Delorme; Patsy Vegh; Leslle Berry; Hugh Hoogendoorn; Maureen Andrew

doi:10.1055/s-0038-1649837

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1995; 74(03): 859-863
DOI: 10.1055/s-0038-1649837

Original Article

Clinical Studies

Schattauer GmbH Stuttgart

Circulating Dermatan Sulfate and Heparan Sulfate/Heparin Proteoglycans in Children Undergoing Liver Transplantation

Lesley Mitchell

¹The Department of Pediatrics, Children’s Hospital at Chedoke-McMaster, Hamilton, Ontario, Canada

,

Ricardo Superina

²The Department of Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada

,

Michael Delorme

³The Department of Medicine, St. Joseph’s Health Centre, London, Ontario, Canada

,

Patsy Vegh

¹The Department of Pediatrics, Children’s Hospital at Chedoke-McMaster, Hamilton, Ontario, Canada

,

Leslle Berry

¹The Department of Pediatrics, Children’s Hospital at Chedoke-McMaster, Hamilton, Ontario, Canada

,

Hugh Hoogendoorn

⁴The Department of Medicine, McMaster University Medical Centre, Hamilton, Ontario, Canada

,

Maureen Andrew

¹The Department of Pediatrics, Children’s Hospital at Chedoke-McMaster, Hamilton, Ontario, Canada

› Institutsangaben

Abstract

als PDF herunterladen

Summary

The liver produces dermatan sulfate (DS), heparan sulfate (HS) and heparin glycosaminoglycans (GAG) and in the presence of hepatic disease, tissue levels of the DS GAG increase dramatically. We hypothesized that in children undergoing liver transplantation plasma levels of DS would be increased. Plasma from children undergoing liver transplantation were tested preoperative, intra operative and post operative at 24-48 h, and 1-3 weeks. Fluctuating levels of DS, HS and heparin anticoagulant activity were detected at all timepoints. The anticoagulant activity was purified and gel chromatography of the material displayed a mean Mr 110,000 D. Reductive elimination decreased the mean Mr 24,000 D indicating the activity resides on a proteoglycan (PG). The purified material was subjected to further chromatography and two peaks of anticoagulant activity resolved, compatible with at least two separate PGs, one with DS GAG chains and the additional PG(s) with HS and heparin GAG chains.

PDF (380 kb)

Referenzen

References
1 Butler P, Israel L, Nusbacher J, Jenkins DE, Starzl TE. Blood transfusion in liver transplantation. Transfusion 1985; 25: 120-123
2 Nusbacher J. Blood transfusion support in liver transplantation. Trans Med Rev 1991; 3: 207-213
3 Vacanti JP, Lillehei CW, Jenkins RL, Donahue PK, Cosimi R, Kleinman R, Grand SI. Liver transplantation in children: the Boston centre experience in the first 30 months. Transplantation Proceedings 1987; 4: 3261-3266
4 Kojima J, Nakamura N, Kanatani M, Ohmori K. The glycosaminoglycans in human hepatic cancer. Cancer Res 1975; 35: 542-547
5 Murata K, Akashio K, Ochiai Y. Changes in acidic glycosaminoglycan components at different stages of human liver cirrhosis. Hepato-gastroenterol 1984; 31: 261-265
6 Murata K, Ochiai Y, Akashio K. Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages of liver cirrhosis. Gastroenterology 1985; 89: 1248-1252
7 Smedsrod B, Kjellän L, Pertoft H. Endocytosis and degradation of chondroitin sulphate by liver endothelial cells. Biochem J 1985; 229: 63-71
8 Gallagher JT, Walker A, Lyon M, Evans WH. Heparan sulphate-degrading endoglycosidase in liver plasma membranes. Biochem J 1988; 250: 719-726
9 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1980; 260: 2218-2224
10 Dupouy D, Sie P, Dol F, Boneu B. A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma. Thromb Haemost 1988; 60: 236-239
11 van der Heiden RM, Hatton M, Moore S. Extraction and analysis of glycosaminoglycans from intima-media of single rabbit aortae: effect of ballon catheter de-endothelialization on the content and profile of glyeosaminoglycans. Atherosclerosis 1988; 73: 203-213
12 Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khamhalia B. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992; 89: 321-326
13 Reding R, Feyaerts A, de Ville de Goyel J, de Hemptinne B, Otte JB. Parly graph loss after fliver transplantation: etiology, chronology and prognosis. Transplantation Proceedings 1991; 23: 1487-1488
14 Murata K, Horiuchi Y. Molecular weight-dependent distribution of acidic glycosaminoglycans in human plasma. Clin Chim Acta 1977; 75: 59-69
15 Ofosu FA, Modi GJ, Blajchman MA, Buchanan MR, Johnson EA. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate. Biochem j 1987; 248: 889-896
16 Van Ryn-McKenna J, Ofosu FA, Hirsh J, Buchanan MR. Antithrombotic and bleeding side effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-269
17 Poole AR. Proteoglycans in health and disease: structure and functions. Biochem J 1986; 236: 01-14
18 Nader HB, Dietrich CP, Buonassisi V, Colburn P. Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc Natl Acad Sci USA 1987; 84: 3565-3569
19 Hirsh HeparinJ. N Engl J Med 1991; 324: 1565-1574
20 Prandoni P, Meduri F, Cuppini S, Tonialo A, Zangrandi F, Polistena P, Gianese F, Faccioli AM. Dermatan Sulfate: a safe approach to prevention of postoperative deep vein thrombosis. Br J Surg 1992; 79: 505-509